Page last updated: 2024-08-18

xanthenes and Atherosclerotic Parkinsonism

xanthenes has been researched along with Atherosclerotic Parkinsonism in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19904 (80.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andrade, PB; Guedes-Dias, P; Leitão-Rocha, A; Oliveira, JM; Pinho, BR; Quintas, C; Reis, SD; Santos, MM; Valentão, P1
Kondo, K; Matsumura, K; Okuda, Y; Takahashi, Y; Yamamoto, T1
Degkwitz, R1
Kingstone, E; Kolivakis, T; Kossatz, I1
Bertuzzi, F; Dogliani, P; Senini, G1

Reviews

1 review(s) available for xanthenes and Atherosclerotic Parkinsonism

ArticleYear
[l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
    Medizinische Klinik, 1969, Aug-15, Volume: 64, Issue:33

    Topics: Acetylcholine; Basal Ganglia; Butyrophenones; Chorea; Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Humans; Methyldopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Reserpine; Tranquilizing Agents; Xanthenes

1969

Trials

1 trial(s) available for xanthenes and Atherosclerotic Parkinsonism

ArticleYear
Double blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics.
    Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology, 1970, Volume: 3, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Aspartate Aminotransferases; Blood Pressure; Body Weight; Chlorpromazine; Clinical Trials as Topic; Female; Humans; Liver Function Tests; Male; Middle Aged; Parkinson Disease, Secondary; Perphenazine; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Vision Disorders; Xanthenes; Xerostomia

1970

Other Studies

3 other study(ies) available for xanthenes and Atherosclerotic Parkinsonism

ArticleYear
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pharmacological research, 2016, Volume: 103

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Behavior, Animal; Benzamides; Diencephalon; Disease Models, Animal; Histone Deacetylase 1; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Indoles; Larva; Locomotion; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Pyridines; RNA, Messenger; Tyrosine 3-Monooxygenase; Xanthenes; Zebrafish; Zebrafish Proteins

2016
[Treatment of Parkinsonism with Tremarial (SJ-1977)].
    No to shinkei = Brain and nerve, 1967, Volume: 19, Issue:7

    Topics: Adolescent; Adult; Atropine; Female; Humans; Male; Middle Aged; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Piperidines; Schizophrenia; Xanthenes

1967
Clinical observations on the therapeutic activity of flupentixol in the treatment of chronic schizophrenia.
    Arzneimittel-Forschung, 1970, Volume: 20, Issue:8

    Topics: Adult; Aged; Blood; Body Weight; Chlorpromazine; Chronic Disease; Delusions; Depression, Chemical; Female; Hallucinations; Humans; Hypnotics and Sedatives; Male; Middle Aged; Orphenadrine; Parkinson Disease, Secondary; Piperazines; Psychomotor Disorders; Psychopharmacology; Schizophrenia; Social Behavior; Stimulation, Chemical; Transaminases; Xanthenes

1970